The Cardiovascular,Coagulation and Haematological Effects of Tiger Snake (Notechis scutatus) Prothrombin Activator and Investigation of Release of Vasoactive Substances
Free accessResearch articleFirst published online October, 1997
The Cardiovascular,Coagulation and Haematological Effects of Tiger Snake (Notechis scutatus) Prothrombin Activator and Investigation of Release of Vasoactive Substances
The cardiovascular, coagulation and haematological effects of prothrombin activator from Tiger Snake (Notechis scutatus) venom were investigated in anaesthetized mechanically ventilated dogs. Infusion caused dose-related systemic hypotension, marked decreases in cardiac output and stroke volume, marked increases in pulmonary artery pressure, pulmonary artery occlusion pressure and pulmonary vascular resistance. Effects occurred within several minutes but abated over 30 to 40 minutes. Evidence of procoagulation included prolongation of prothrombin and partial thromboplastin times and depletion of serum fibrinogen. Thrombocytopenia and leucopenia occurred. All effects were prevented by prior administration of heparin but none by inhaled nitric oxide. Oesophageal echocardiography during infusion identified thrombi within the heart, right ventricular dilatation and dyskinesia. Electrocardiography suggested myocardial ischaemia. Pulmonary thromboemboli were identified histologically post mortem. Cardiovascular effects of the activator were not due to a variety of endogenous substances as indicated by use of antagonists to platelet activating factor and thromboxane A2, indomethacin, dexamethasone, serotonin, ketanserin, histamine, promethazine and ondansetron. Tiger Snake prothrombin activator causes bilateral ventricular failure by thrombotic obstruction of the pulmonary vasculature and possibly by coronary ischaemia.
TibballsJ.The cardiovascular, coagulation and haematological effects of tiger snake (Notechis scutatus) venom.Anaesth Intensive Care1998; 26: 529–535.
2.
FrancisB., JohnT.R., SeebartC., KaiserI.I.New toxins from the venom of the common Tiger Snake (Notechis scutatus).Toxicon1991; 29: 85–96.
3.
TansG., Govcrs-ReimslagJ.W.P., van RijnJLML, RosingJ.Purification and properties of a prothrombin activator from the venom of Notechis scutatus.J Biol Chem1985; 260: 9366–9370.
4.
MarshallL.R., HerrmannR.P.Australian snake venoms and their in vitro effect on human platelets.Thrombos Res1989; 54: 269–275.
5.
BarnesP.J., HensonP.M.Platelet-activating factor. In: CrystalR.G., WestJ.B., BarnesP.J., CherniackNS, WebelE.R. eds. The Lung, Scientific Foundations.Raven Press Ltd, New York1991; 49–59.
6.
PiperP.J., StewartA.G.Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.Br J Pharmacol1987; 90: 771–783.
FryB.G.Structure-function properties of venom components from Australian elapids. Centre for Drug Design and Development, University of Queensland, St Lucia, Qld (undated).
10.
FrancisB., CoffieldJ.A.Simpson LL, Kaiser H.Amino acid sequence of a new type of toxic phospholipase Λ2 from the venom of the Australian Tiger Snake (Notechis scutatus). Arch Biochem Biophys1995; 318: 481–488.
11.
CamussiG., AgliettaM., MalavasiF.The release of platelet-activating factor from human endothelial cells in culture.J Immunol1983; 131: 2397–2403.
12.
ChignardM., LeCouedicJ.P., VargaftigB.B., BenvenisteJ.Platelet-activating factor (PAF-accther) secretion from platelets; effect of aggregating agents.Br J Haematol1980; 46: 455–464.
13.
PrescottSM., ZimmermanGA, McIntyreTM.Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin.Proc Natl Acad Sci USA1984; 81: 3534–3538.
14.
EzraD., LaurindoF.R., CzajaJF., SnyderF., GoldsteinR.E., FeuersteinG.Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig.Prostaglandins1987; 34: 41–57.
15.
SybertzE.J., WatkinsR.W., BaumT., PulaK., RivelliM.Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anaesthetized dog.J Pharmacol Exp Ther1985; 232: 156–162.
16.
DelbridgeL.M., StewartA.G., GoulterCM., MorganT.O., HarrisP.J.Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility.J Molecular Cellular Cardiol1994; 26: 185–193.
17.
RobertsonD.A., GenoveseA., LeviR.Negative inotropic effect of platelet-activating factor on human myocardium: a pharmacological study.J Pharmacol Exp Ther1987; 243: 834–839.
18.
da SilvaM.B., HerionF., RaskinetR., DavidJ.L., GustinP., LekeuxP.Combined effect of WEB 2086 (Paf antagonist) and keto-profen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine.Zentralblatt Fur Veterinarmedizin-Reihe A1997; 44: 65–71.
19.
WilsonD.V., EberhartS.W., RobinsonN.E., RiceR.Gray PR. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anaesthetized ponies, and the effects of a PAF antagonist, WEB 2086.Am J Vet Res1993; 54: 274–279.
20.
BillsT.K., SmithJB., SilverM.I. Selective release of arachidonic acid from the phospholipids of human platelets in response to thrombin.J Clin Invest1977; 60: 1–6.
21.
OgletreeM.L.Overview of physiological and pathophysiological effects of thromboxane A2. A review.Fed Proc1987; 46: 133–138.
22.
YamanakaS., MiuraK., YukimuraT., YamamotoK.11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs.Prostaglandins1993; 45: 221–228.
BlaekwellG.J., FlowerR.J., NijkampF.P., VaneJ.R.Phospholipase A2 activity of guinea pig isolated perfused lungs: Stimulation and inhibition by anti-inflammatory steroids.Br J Pharmacol1978; 62: 79–89.
25.
ShamsH., SchulzH., MohrM.Cyelooxygenase inhibition and effects of hypoxia on pulmonary circulation and gas exchange in anesthetized dogs.Resp Physiol1989; 75: 39–49.
26.
McCallR.B., ClementM.E.Role of serotoninIA and serotonin2 receptors in the central regulation of the cardiovascular system.Pharmacol Rev1994; 46: 231–243.
27.
LindenA.S., DesmechtD.J., AmoryH., BeduinJ.M., LekeuxP.M.Cardiovascular responses to exogenous serotonin in healthy calves.Am J Vet Res1996; 57: 731–738.
28.
BreuerJ., GeorgarakiA., SieverdingL., BadenW., ApitzJ.Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease.Ped Cardiol1996; 17: 214–219.
29.
el-KashefH.Hyperglycaemia increased the responsiveness of isolated rabbit's pulmonary artery rings to serotonin.Pharmacol1996; 53: 151–159.
30.
FeldbergW., KellawayC.H.The circulatory and pulmonary effects of the venom of the Australian copperhead (Denisonia superba).Aust J Exp Biol Med Sci1937; 15: 81–95.
31.
GenoveseA., SpadaroG.Highlights in cardiovascular effects of histamine and H1-receptor antagonists.Allergy1997; 52: 67–78.
32.
AltmanD.G.Practical statistics for medical research.Chapman & Hall, London1991.
33.
TibballsJ., HochmannM., CarterB., OsborneA.An appraisal of techniques for administration of gaseous nitric oxide.Anaesth Intensive Care1993; 23: 844–847.
34.
MorrisonJ.J., PearnJ.H., CoulterA.R.The mass of venom injected by two elapidae: the Taipan (Oxyuranus scutellatus) and the Australian Tiger snake (Notechis scutatus).Toxicon1982; 20: 739–745.
35.
FeldbergW., KellawayC.H.Liberation of histamine from the perfused lung by snake venoms.J Physiol1937; 90: 257–279.
36.
WhitakerA.N., McKayD.G.Induction of hypotension in Rhesus monkeys and rabbits by intravenous thrombin infusion.Lab Invest1969; 20: 79–86.
37.
SchneiderC.L., EngstromR.M.Experimental pulmonary arterial occlusion. Acute cor pulmonale simulating “obstetrical shock” of late pregnancy.Am J Obstet Gynec1954; 68: 691–705.
RadomskiM.W., PalmerR.M.J., MoncadaS.An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.Proc Natl Acad Sci USA1990; 87: 5193–5197.
40.
GolinoP., Cappelli-Bigazzi in AmbrosioG.Endothelium-derived relaxing factor modulates platelet aggregation in an vivo model of recurrent platelet activation.Circ Res1992; 71: 1447–1456.
41.
FreedmanJ.E., LoscalzoJ., BarnardM.R., AlpertC., KeaneyJ.F., MiehelsonA.D.Nitric oxide released from activated platelets inhibits platelet recruitment.J Clin Invest1997; 100: 350–356.
42.
KehD., GerlachM.Kurer I, et al. The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human alpha-thrombin.Blood Coagulation & Fibrinolysis1996; 7: 615–624.
43.
RadomskiM.W., VallanceR, WhitleyG., FoxwellN., MoncadaS.Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide.Cardiovase Res1993; 27: 1380–1382.
44.
De CaterinaR., LibbyP., PengM.B.. Nitric oxide decreases eytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.J Clin Invest1995; 96: 60–68.
45.
AdamsM.R., JessupW., HailstonesD.Celermajer DS. L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules.Circulation1997; 95: 662–668.
46.
HuW., McNichollI.K., ChoyP.C., ManR.Y.Partial agonist effect of the platelet-activating receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart.Br J Pharmacol1993; 110: 645–650.
